Setidegrasib demonstrates favorable safety and promising clinical activity in advanced KRAS G12D-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
ELCC 2026
Related content
Lung, Respiratory and Thoracic Cancer
Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland
J Med Econ
Wislez M, Giannopoulou A, Borget I, Lindsay C, Rothschild SI, Vincent B, Milce J, Sultan I, Stollenwerk B, Pless M
doi: 10.1080/13696998.2025.2535225
ELCC 2026
Lung, Respiratory and Thoracic Cancer
PALOMA-2: Durable clinical outcomes and manageable safety with SC amivantamab plus lazertinib in patients with EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial
Lung Cancer
Dingemans AC, Syrigos K, Livi L, Paulus A, Kim SW, Chen Y, Felip E, Griesinger F, Ohashi K, Zalcman G, Hughes BGM, Sørensen JB, Blais N, Ferreira CGM, Lindsay CR, Dziadziuszko R, Ward PJ, Obiozor CC, Wang Y, Peters S
doi: 10.1016/j.lungcan.2025.108683
Lung, Respiratory and Thoracic Cancer
Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
Adv Ther
Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B
doi: 10.1007/s12325-025-03259-8
WCLC 2025
Lung, Respiratory and Thoracic Cancer
FLAURA2: Frontline osimertinib plus chemotherapy significantly improves OS in EGFR-mutated advanced NSCLC
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*
Lung, Respiratory and Thoracic Cancer
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival
Lung Cancer
Eklund EA, Orgard M, Wallin D, Sayin SI, Fagman H, Isaksson J, Raghavan S, Akyürek LM, Nyman J, Wiel C, Hallqvist A, Sayin VI
doi: 10.1016/j.lungcan.2025.108573
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
★ 3
Recommended by
Dr Martin Frey, Faculty Member
N Engl J Med
Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, Li X, Zhuang W, Fang J, Wang Q, Jiang W, Li K, Bai Y, Luo Y, Ma F, Yu Y, Zheng W, Liu Z, Yang B, Ma R, Fang Y, Yang R, Jiang L, Hu J, Yang J, Diao Y, Jin X, Ge J, Yang Y, Zhang L
doi: 10.1056/NEJMoa2512071
SABCS 2025
Breast Cancer